Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

• Published in: Annals of the rheumatic diseases Vol. 77; no. 12; p. 1710
• Main Authors: Ruperto, Nicolino, Brunner, Hermine I, Quartier, Pierre, Constantin, Tamàs, Wulffraat, Nico M, Horneff, Gerd, Kasapcopur, Ozgur, Schneider, Rayfel, Anton, Jordi, Barash, Judith, Berner, Reinhard, Corona, Fabrizia, Cuttica, Ruben, Fouillet-Desjonqueres, Marine, Fischbach, Michel, Foster, Helen E, Foell, Dirk, Radominski, Sebastião C, Ramanan, Athimalaipet V, Trauzeddel, Ralf, Unsal, Erbil, Levy, Jérémy, Vritzali, Eleni, Martini, Alberto, Lovell, Daniel J
• Format: Journal Article
• Language: English
• Published: England 01-12-2018
• Subjects: Adolescent; Antibodies, Monoclonal - therapeutic use; Antirheumatic Agents - therapeutic use; Arthritis, Juvenile - drug therapy; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; Treatment Outcome; Young Adult; clinical trial; systemic juvenile idiopathic arthritis; canakinumab; long-term extension; interleukin-1β
• ISSN: 1468-2060
• DOI: 10.1136/annrheumdis-2018-213150

To evaluate the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis (JIA).
Patients (2-19 years) entered two phase III studies and continued in the long-term extension (LTE) study. Efficacy assessments were performed every 3 months, including adapted JIA American College of Rheumatology (aJIA-ACR) criteria, Juvenile Arthritis Disease Activity Score (JADAS) and ACR clinical remission on medication criteria (CR
). Efficacy analyses are reported as per the intent-to-treat population.
144 of the 177 patients (81%) enrolled in the core study entered the LTE. Overall, 75 patients (42%) completed and 102 (58%) discontinued mainly for inefficacy (63/102, 62%), with higher discontinuation rates noted in the late responders group (n=25/31, 81%) versus early responders (n=11/38, 29%). At 2 years, aJIA-ACR 50/70/90 response rates were 62%, 61% and 54%, respectively. CR
was achieved by 20% of patients at month 6; 32% at 2 years. A JADAS low disease activity score was achieved by 49% of patients at 2 years. Efficacy results were maintained up to 5 years. Of the 128/177 (72.3%) patients on glucocorticoids, 20 (15.6%) discontinued and 28 (22%) tapered to 0.150 mg/kg/day. Seven patients discontinued canakinumab due to CR. There were 13 macrophage activation syndrome (three previously reported) and no additional deaths (three previously reported). No new safety findings were observed.
Response to canakinumab treatment was sustained and associated with substantial glucocorticoid dose reduction or discontinuation and a relatively low retention-on-treatment rate. No new safety findings were observed on long-term use of canakinumab.
NCT00886769, NCT00889863, NCT00426218 and NCT00891046.